EDWARDS LIFESCIENCES CORP

NYSE: EW (Edwards Lifesciences Corporatio)

Last update: yesterday, 4:42AM

105.23

-0.20 (-0.19%)

Previous Close 105.43
Volume 3,922,194
Price / Earnings (Forward) 30.74
Price / Sales 9.15
Price / Book 5.59
52 Weeks Range
74.66 (-29%) — 108.00 (2%)
Profit Margin 75.71%
Operating Margin (TTM) 29.01%
Diluted EPS (TTM) 2.42
Quarterly Revenue Growth (YOY) 6.20%
Quarterly Earnings Growth (YOY) 1.70%
Total Debt/Equity (MRQ) 6.86%
Current Ratio (MRQ) 4.45
Operating Cash Flow (TTM) 876.20 M
Levered Free Cash Flow (TTM) 1.45 B
Return on Assets (TTM) 8.42%
Return on Equity (TTM) 16.51%

AIStockmoo Score

0.3
The price implies earnings growth of 22.6% a year; the business can fund about 15.0% a year. info
Dearer than its usual valuation. info
Earns well above its cost of capital. Returns on capital falling. info
Low debt. Strong profitability. Ample short-term liquidity. Positive cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
No clear trend over the past year. Trading near its 52-week high. info
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. Volume is heavier on up days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Holdings' Sentiment info NA
No clear net insider buying or selling. info
Institutions net -1.37% of shares in their latest 13F filings: 620 holders increased, 619 decreased (quarter to 30 Sep 2026). info
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Earnings per share have mostly fallen. Earnings have been uneven. info
Above its medium-term trend line. info
Price is high against its 52-week average. info
Trend up on all three terms. Short-term momentum rising. info
Price is near resistance. info
Final Score 0.25
Show all

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Mixed
Medical Devices (Global) Mixed Mixed
Stock Edwards Lifesciences Corporatio Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
EW - - - 5.59 0.3
SNN 12 B 1.31% 20.29 2.47 0.0
SYK - 1.05% - 5.07 -0.2
BSX - - - 2.51 -0.5
ABT 178 B 2.43% 38.43 3.55 0.0
MDT 131 B 2.83% 25.09 2.57 1.9

Select this tab to load the latest available analysis.

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Sector Healthcare
Industry Medical Devices
Investment Style Mid Growth
% Held by Insiders 0.91%
% Held by Institutions 89.29%

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BOBO DONALD E JR - 104.71 -48,900 -5,120,319
LIPPIS DANIEL J. - 104.01 -619 -64,382
ZOVIGHIAN BERNARD J - 104.71 -23,100 -2,418,801
Aggregate Net Quantity -72,619
Aggregate Net Value ($) -7,603,502
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 104.70
Name Holder Date Type Quantity Price Value ($)
LIPPIS DANIEL J. Officer 10 Nov 2026 Automatic sell (-) 619 104.01 64,382
LIPPIS DANIEL J. Officer 10 Nov 2026 Option execute 619 - -
BOBO DONALD E JR Officer 09 Nov 2026 Automatic sell (-) 48,900 104.71 5,120,319
BOBO DONALD E JR Officer 09 Nov 2026 Option execute 48,900 - -
ZOVIGHIAN BERNARD J Officer 09 Nov 2026 Automatic sell (-) 23,100 104.71 2,418,801
ZOVIGHIAN BERNARD J Officer 09 Nov 2026 Option execute 23,100 - -

Institutions

Institutional ownership: 102.67%

Positions Holders Shares
Increased 620 30,985,940
Decreased 619 36,588,396
New 137 4,425,812
Sold out 105 6,700,075

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

10 Positive 2 Negative 2 Neutral
Date Type Details
16 Nov 2026 Yahoo Finance Are Wall Street Analysts Predicting Edwards Lifesciences Stock Will Climb or Sink?
Edwards Lifesciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.
13 Nov 2026 Yahoo Finance Is There Any Reason To Invest In Edwards Lifesciences Stock?
For questions about this article or underlying research, email [email protected].
13 Nov 2026 Yahoo Finance A $9.2 Billion Fund Dumps These 3 Stocks
Key TakeawaysA fund with $9. 2 billion in US stocks sold all of its Edwards Lifesciences, PepsiCo and ServiceNow shares in the third quarter, about a tenth of its portfolio at June 30…
07 Nov 2026 Yahoo Finance Edwards Lifesciences Q3 Earnings Call Highlights
Edwards Lifesciences (NYSE:EW) raised its 2026 sales and earnings guidance after third-quarter results exceeded management’s expectations, with growth across its heart-valve businesses and regions. The medical device maker reported sales of $1.72 billion, up 11.2% from a year earlier, and adjusted…
05 Nov 2026 Yahoo Finance Edwards Life (EW) Q3 2026 Earnings Call Transcript
Edwards raised its sales outlook after a quarter that beat internal projections.
05 Nov 2026 Yahoo Finance CAH Shares Post New Record, EW Stock Hits Over Three-Year High – What’s Driving Today’s Rally?
Cardinal Health reported a 5% increase in Q1 revenue, beating Wall Street’s forecast, while analysts raised Edwards Lifesciences’ price target after a better-than-expected Q3 print.
05 Nov 2026 Yahoo Finance Edwards Lifesciences Corp (EW) (Q3 2026) Earnings Call Highlights: Broad-Based TAVR and TMTT ...
Edwards Lifesciences Corp (EW) posted 11.2% sales growth to $1.72 billion and lifted full-year adjusted EPS guidance to $2.97--$3.05, as TMTT surged 45.6% and TAVR grew 8.8%.
05 Nov 2026 Yahoo Finance Edwards bumps up sales forecast on TAVR strength in Q3
Going forward, the heart valve maker expects procedure volumes to rise following positive study data and expanded Medicare reimbursement.
05 Nov 2026 Yahoo Finance Edwards Lifesciences (EW) Trial Data Points To Earlier TAVR Use In Moderate Aortic Stenosis
Edwards Lifesciences (NYSE:EW) reported new PROGRESS Trial data showing transcatheter aortic valve replacement outperformed active surveillance in moderate aortic stenosis. The trial linked TAVR use in moderate aortic stenosis with fewer combined outcomes of death or heart failure events in at-risk…
05 Nov 2026 Yahoo Finance Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs
EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance.
04 Nov 2026 Yahoo Finance Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif., November 04, 2026--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026…
04 Nov 2026 Yahoo Finance Edwards Lifesciences (EW) Trial Win Puts Fair Value Back In Focus
Edwards Lifesciences (EW) is back in focus after new data showed its PASCAL tricuspid repair system outperformed medical therapy in the CLASP II TR trial, with benefits sustained through one year. Recent data and regulatory milestones have come alongside clear momentum in the Edwards Lifesciences…
03 Nov 2026 Yahoo Finance Edwards Lifesciences' Progress Data Unlikely to Expand TAVR Market, RBC Says
Edwards Lifesciences' (EW) Progress trial is unlikely to meaningfully expand the market for transcat…
02 Nov 2026 Yahoo Finance Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits
Edwards Lifesciences (NYSE:EW) highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic st…
Show more

Technical Setup Medium

Trend order
Slope
Entry
Volume
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. Volume is heavier on up days.
Nearest support: 95.59 – 96.99 · moderate level
Nearest resistance: 107.30 – 108.70 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria